From Lost in Translation to Paradise Found: Enabling Protein Biomarker Method Transfer by Mass Spectrometry
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Recently, Begley and Ellis delivered a sobering message to laboratories around the world (1). The lack of meaningful progress in preclinical cancer research was highlighted by the irreproducibility of >70% of published studies. The authors also crystallized the importance of full disclosure and the validation of critical scientific discoveries for industry-wide improvement. Translation of novel biomarkers into clinical care for the evaluation of therapeutic safety and efficacy has been slow (2), partly because of the cost and complexity of immunoassay development. The potential for liquid chromatography–tandem mass spectrometry (LC-MS/MS)3 to streamline the translation of novel protein biomarkers is profound (3). Most LC-MS/MS-based protein assays incorporate denaturation and proteolytic digestion of proteins in the sample into peptides (traditionally called “bottom-up” proteomics). These preparative steps destroy potentially interfering proteins into peptides that can be resolved and ignored by LC-MS/MS (4). Inclusion of stable isotope–labeled internal standard proteins or peptides (which may be cleavable) in each sample enables correction for matrix effects, including sample-related digestion variability and/or ion suppression, both significant analytical benefits compared with immunoassays. Downstream members of the scientific community are hopeful about translating important preliminary findings into clinical practice; however, success has been hampered by a lack of transparency and insufficient validation. Consequently, LC-MS/MS-based clinical protein analysis has predominantly focused on improved analytical measurement for well-established biomarkers (5). This is despite “fit-for-purpose” criteria for enablement (6, 7) and published recommendations for analytical validation (8), based primarily on U.S. Food and Drug Administration guidance (9). Although assays used in preclinical research are generally not held to the same standards as assays used in the immediate care of patients, which are governed by CLIA-88 and by extension many Clinical Laboratory Standards Institute consensus documents, published fundamental discovery experiments and biomarker verification studies spawn costly research programs. To advance our efforts as a community, LC-MS/MS protein quantification data used to support published research findings should be from properly designed studies (10) and accompanied by a standard operating procedure that includes sufficient detail to facilitate assay reproduction in other laboratories. The careful definition of the measurand is essential (11). Appropriate method validation should include experiments that evaluate and document key analytical performance characteristics. To this end, we present and discuss a minimal list of experiments (Table 1) that would allow downstream users of novel biomarkers to carefully evaluate their quality and potential reproducibility. Although certain experiments are uniquely associated with bottom-up LC-MS/MS proteomics work flows, we believe that there are universally applicable concepts described within this document that should be applied to alternate technologies in biomarker translation. Given the lessons of the past (1), we cannot overemphasize the importance of this level of transparency and rigor in the publication of novel scientific discoveries. Best practice acceptance criterion as defined by Lee et al. (7), acknowledged as a hybrid of immunoassays and LC-MS/MS validation criteria derived from DeSilva et al. (8). Best practice acceptance criterion as defined by Lee et al. (7), acknowledged as a hybrid of immunoassays and LC-MS/MS validation criteria derived from DeSilva et al. (8). For the vast majority of clinical and preclinical assays, precise measurements facilitate longitudinal monitoring of disease, resolution of the disease continuum with confidence, and hypothesis verification. The imprecision of an assay can be assessed within batches (repeatability) or longitudinally and between laboratories (reproducibility). We propose the use of 2 pools, presumably with different concentrations, for the marker of interest: a disease pool comprising equal volumes of known disease samples (ideally n = 20) and a healthy pool (n = 400, derived from Ichihara et al. (12)). We have recently collaborated to enable a commercial source of pools from healthy controls (EDTA plasma and serum, men or women 20–50 years old, Golden West Biologicals). An estimation of total variability per pool should be determined from 5 individual replicates of each pool assayed each day for 5 days. The mean intra-assay (CVintra) and inter-assay (CVinter) CVs for each pool should be calculated. CVintra includes all 5 replicates (1–5) per pool measured in a single day. CVinter is determined for each replicate individually across all 5 days (CV for replicate 1 across 5 days, replicate 2 across 5 days, etc.). The total variability is determined by use of the mean CVintra (across 5 days)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979 · cited 1×
“Given the lessons of the past (1), we cannot overemphasize the importance of this level of transparency and rigor in the publication of novel scientific discoveries.”
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867
Carr, S. A., Abbatiello, S. E., Ackermann, B. L., Borchers, C., Domon, B., Deutsch, E. W., Grant, R. P., Hoofnagle, A. N., Hüttenhain, R., Koomen, J. M., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.036095 · Cited by 561
Self-citationAgger, S. A., Marney, L. C., & Hoofnagle, A. N. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.152264 · Cited by 143
Self-citation
Cited by
Revisiting biomarker discovery by plasma proteomics
Geyer, P. E., Holdt, L. M., Teupser, D., & Mann, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20156297 · Cited by 917
Automated sample preparation with SP 3 for low‐input clinical proteomics
Müller, T., Kalxdorf, M., Longuespée, R., Kazdal, D. N., Stenzinger, A., & Krijgsveld, J. (2020) · Molecular Systems Biology · doi:10.15252/msb.20199111 · Cited by 295
Nakayasu, E. S., Gritsenko, M., Piehowski, P. D., Gao, Y., Orton, D. J., Schepmoes, A. A., Fillmore, T. L., Frohnert, B. I., Rewers, M., Krischer, J. P., et al. (2021) · Nature Protocols · doi:10.1038/s41596-021-00566-6 · Cited by 275
Clinical potential of mass spectrometry-based proteogenomics
Zhang, B., Whiteaker, J. R., Hoofnagle, A. N., Baird, G. S., Rodland, K. D., & Paulovich, A. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0135-7 · Cited by 210
Self-citationHenderson, C. M., Lutsey, P. L., Misialek, J. R., Laha, T. J., Selvin, E., Eckfeldt, J. H., & Hoofnagle, A. N. (2016) · Clinical Chemistry · doi:10.1373/clinchem.2015.244541 · Cited by 140
“In the validation of the assay presented herein, we followed the recommendations that we recently published (32).”
MethodSelf-citation
Metadata
- Authors
- Grant, R. P., & Hoofnagle, A. N.
- Venue
- Clinical Chemistry
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-07-01
- Volume
- 60
- Issue
- 7
- Pages
- 941-944
- ISSN
- 0009-9147 (ISSN-L)
- 1530-8561
- OpenAlex
- W2110958540
- Cited by
- 117
- References
- 4
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: From Lost in Translation to Paradise Found: Enabling Protein Biomarker Method Transfer by Mass Spectrometry. https://app.cochat.ai/papers/10.1373/clinchem.2014.224840
- The paper
- Grant, R. P., & Hoofnagle, A. N. (2014). From Lost in Translation to Paradise Found: Enabling Protein Biomarker Method Transfer by Mass Spectrometry. Clinical Chemistry. https://doi.org/10.1373/clinchem.2014.224840
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.